MISSISSAUGA, Ontario -- August 9, 2010 -- After priority review, Health Canada has approved trastuzumab (Herceptin), in combination with capecitabine (Xeloda) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic adenocarcinoma of the stomach or gastroesophageal cancer.
The approval is based on the results from the international ToGA trial, which showed that trastuzumab significantly...
CHICAGO — A phase 3 clinical trial failed to demonstrate the superiority of treatment using sunitinib plus capecitabine compared with capecitabine alone for patients with previously treated advanced breast cancer.
John Crown, MD, consultant medical oncologist at St Vincent’s Hospital in Dublin, presented data from the trial, which sought to investigate the antiangiogenic agent, sunitinib (Sutent, Pfizer), in combination...
New agents improve survival time at high cost in metastatic colorectal cancer patients
HemOnc today
Posted May 6, 2010
New chemotherapeutic agents used to treat metastatic colorectal cancer were shown to have high costs associated with their survival benefits, although the costs fell below common estimates of willingness-to-pay amounts for a life-year.
Between 1996 and 2004, several chemotherapy agents were approved to treat patients with metastatic...
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GETA.OB) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s request for “Fast Track” designation of tesetaxel for treatment of patients with advanced gastric cancer. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.
Fast Track designation is designed to facilitate...
Æterna Zentaris Announces Perifosine Receives FDA Fast Track Designation for the Treatment of Refractory Advanced Colorectal Cancer
QUEBEC CITY, April 5 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. ( AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals ( KERX), was granted Fast Track designation by the U.S. Food and Drug Administration ("FDA")...
